Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale. Sloan exercised stock options to acquire 8,333 shares of common stock at $27.46 per share, then sold 8,333 shares in an open‑market transaction at $75.00 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Sloan continues to hold 8,333 common shares directly and 313,334 stock options exercisable for common stock, with the option award originally covering 400,000 shares and expiring on October 1, 2034.
Spyre Therapeutics, Inc. reported that Chief Executive Officer and director Cameron Turtle sold a total of 15,000 shares of common stock in three open-market transactions on June 1, 2026 at prices ranging from the high-$60s to low-$70s per share. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, indicating they were pre-arranged. Following the transactions, the filing shows Turtle directly holding 597,540 shares of common stock, which includes 87,138 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction. On June 1, 2026, he exercised options to acquire 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in three open-market trades at weighted-average prices around the low $70s, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly holds 105,494 shares of common stock, including 67,476 restricted stock units that vest in equal installments in 2026 and 2027, and continues to hold a large stock option covering hundreds of thousands of additional shares.
SYRE filed a Rule 144 notice reporting a planned sale of 16,667 shares via exercise of stock options on 06/03/2026. The filing also lists prior 10b5-1 sales: 78,333 shares on 05/01/2026 for $5,600,884.57 and 7,958 shares on 04/01/2026 for $397,900.00.
Spyre Therapeutics reported an amendment to its SPY003 license agreement with Paragon Therapeutics. The change expands Spyre’s rights from only inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses for SPY003.
This broader license is subject to dosing limits. Spyre will not dose human patients with SPY003 outside inflammatory bowel disease in a clinical trial as part of a combination before June 1, 2028, or as a monotherapy before June 1, 2030, under what is termed the Monotherapy Dosing Restriction.
If Spyre or a Paragon licensee completes a material transaction, such as a change of control, any remaining restrictions outside the original inflammatory bowel disease field will end on June 1, 2028. The full terms are set out in the filed amendment.
Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds. An option was granted covering 8,026 shares of common stock at an exercise price of $72.51 per share, expiring on May 27, 2036. The option vests in full on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, subject to Mr. Kiselak’s continued service. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock from this option is for the benefit of Fairmount-managed investment vehicles, and Mr. Kiselak disclaims beneficial ownership except for his pecuniary interest.
Spyre Therapeutics, Inc. director Jeffrey W. Albers received a stock option grant covering 8,026 shares of common stock. The option has an exercise price of $72.51 per share and expires on May 27, 2036.
The award vests and becomes fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Albers continues serving the company through that vesting date. Following this grant, he holds options for 8,026 shares directly.
Spyre Therapeutics, Inc. director Michael Thomas Henderson received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual meeting of stockholders, subject to his continued service, leaving him with 8,026 options following this award.
Spyre Therapeutics, Inc. director Laurie Stelzer received a grant of stock options covering 8,026 shares of common stock. The options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The award will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Stelzer continues to serve the company through that vesting date. Following this grant, she holds 8,026 options directly.
Spyre Therapeutics, Inc. director Mark C. McKenna received a grant of stock options covering 8,026 shares of common stock. These options carry an exercise price of $72.51 per share and expire on May 27, 2036.
The options will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual meeting of stockholders, provided McKenna continues serving the company through the vesting date. After this grant, he holds 8,026 derivative securities directly from this award.